ReviewCurrent oncology (Toronto, Ont.)2020
Immunotherapy in soft-tissue sarcoma.
Review in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 110 citations in OpenAlex.
- LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma.Oncoimmunology · 2024Trial
- Ultrasound-Guided Histotripsy for Non-Invasive Treatment of Ex Vivo Soft Tissue Tumors: Preclinical Feasibility Study.Annals of surgical oncology · 2026Article
- A rare incidence of primary pulmonary undifferentiated pleomorphic sarcoma detected as an endobronchial mass and treated by bronchoscopic resection: a case report and literature review.Frontiers in oncology · 2026Article
- Dedifferentiated liposarcoma presenting with ascites as the initial clinical manifestation: a case report and literature review.Frontiers in medicine · 2026Article
- Review
- Enhancing prognostic precision: exploring the role of lung immune prognostic index in immunotherapy-treated soft tissue sarcoma patients-a retrospective study.Journal of orthopaedic surgery and research · 2025Article
- EWS::WT1 Isoform-Dependent Regulation of Neogenes in Desmoplastic Small Round Cell Tumors.bioRxiv : the preprint server for biology · 2025Article
- Potential Mechanisms for Immunotherapy Resistance in Adult Soft-Tissue Sarcoma.Targeted oncology · 2025Review
- Treatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy.International journal of clinical oncology · 2025Review
- Review
- Case Report: Three-year follow-up of TACE for recurrent undifferentiated pleomorphic sarcoma: sustained local control and no systemic progression.Frontiers in oncology · 2025Article
- SECTM1 acts as an immune-related biomarker of poor prognosis and promotes cancer progression by modulating M2 macrophage polarization in esophageal squamous cell carcinoma.Frontiers in immunology · 2025Article
- Identification and comprehensive analysis of an immune-related gene prognostic model for indicating tumor immune microenvironment features in soft tissue sarcoma.Frontiers in oncology · 2025Article
- Targeting cancer stem cells by TPA leads to inhibition of refractory sarcoma and extended overall survival.Molecular therapy. Oncology · 2024Article
- Article
- Trends in the use of immunotherapy to treat soft tissue sarcoma.American journal of surgery · 2024Article
- Jejunal sarcomatoid carcinoma: A case report and review of literature.World journal of gastrointestinal oncology · 2024Article
- A clinical tool to predict overall survival of elderly patients with soft tissue sarcoma after surgical resection.Scientific reports · 2024Article
- Enhancing radiotherapy response via intratumoral injection of a TLR9 agonist in autochthonous murine sarcomas.JCI insight · 2024Article
- Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases.Oncology letters · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft-tissue sarcoma (sts) is a rare mesenchymal malignancy that accounts for less than 1% of all adult tumours. Despite the successful advancement of localized therapies such as surgery and radiotherapy, these tumours can, for many, recur-often with metastatic disease. In the advanced setting, the role of systemic therapies is modest and is associated with poor survival. With the discovery of immunotherapies in other tumour types such as melanoma and lung cancer, interest has been renewed in exploring immunotherapy in sts. The biology of some stss makes them ripe for immunotherapy intervention; for example, some stss might have chromosomal translocations resulting in pathognomonic fusion products that have been shown to express cancer/testis antigens. Here, we present a targeted review of the published data and ongoing clinical trials for immunotherapies in patients with sarcoma, which comprise immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.